Novartis Ag (NVS) Operating Margin (2009 - 2026)
Novartis Ag (NVS) posted Operating Margin of 32.97% for Q2 2026, down 4.74% sequentially from 34.61% in Q2 2025, and down 164.0% YoY from 51.51% in Q2 2025.
Novartis Ag (NVS) Operating Margin (2009 - 2026) Analysis & Trends
Novartis Ag has reported Operating Margin for 18 years, with the latest figure at 32.97% in Q2 2026.
- Quarterly Operating Margin fell 164.0% year-over-year to 32.97% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 277.53% (up 19181.0% YoY) and the FY2025 annual result came in at 32.36%, up 345.0% from the prior year.
- Operating Margin declined to 32.97% in Q2 2026 per NVS's latest filing, from 34.61% in the prior quarter.
- Over five years, Operating Margin peaked at 13229852.53% in Q1 2022 and troughed at 17.43% in Q2 2022.
- A 5-year average of 1343089.89% and a median of 34.61% in 2025 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2023: Operating Margin surged 824739132 bps in 2022, then tumbled 1168640778 bps in 2023.
- Over 5 years, Operating Margin stood at 119.32% in 2022, then sank by 80 bps to 24.4% in 2023, then soared by 396 bps to 120.96% in 2024, then slumped by 71 bps to 34.61% in 2025, then dropped by 5 bps to 32.97% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 32.97%, 34.61%, and 120.96% for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 470.02 Bn | 463.46 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 379.06 Bn | 371.92 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 302.95 Bn | 295.26 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.68 Bn | 252.78 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 236.97 Bn | 222.98 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 182.78 Bn | 179.60 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 161.51 Bn | 149.81 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.54 Bn | 101.37 Bn | 8.24 Bn | 5.72% |
| 10 | Sanofi | 55.04 Bn | 47.66 Bn | 10.79 Bn | 124.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.97% |
| Jun 30, 2025 | 34.61% |
| Dec 31, 2024 | 120.96% |
| Jun 30, 2024 | 32.08% |
| Dec 31, 2023 | 24.40% |
| Jun 30, 2023 | 24.54% |
| Mar 31, 2023 | 1,543,444.75% |
| Dec 31, 2022 | 119.32% |
| Sep 30, 2022 | 285.17% |
| Jun 30, 2022 | 17.43% |
| Mar 31, 2022 | 13,229,852.53% |
| Dec 31, 2021 | 47.49% |
| Sep 30, 2021 | -2,265.63% |
| Jun 30, 2021 | 26.85% |
| Mar 31, 2021 | 4,982,461.21% |
| Dec 31, 2020 | 48.17% |
| Sep 30, 2020 | 7,563,321.01% |
| Jun 30, 2020 | 20.73% |
| Mar 31, 2020 | -18.83% |
| Jun 30, 2019 | 22.64% |